Carbonic Anhydrase IX as a Marker of Disease Severity in Obstructive Sleep Apnea
dc.authorid | KIRAN, TUGBA RAIKA/0000-0002-3724-0249 | |
dc.authorid | Erdem, Mehmet/0000-0002-9100-2479 | |
dc.authorid | Otlu, Onder/0000-0001-5958-7609 | |
dc.authorwosid | Otlu, Onder/W-3887-2018 | |
dc.contributor.author | Geckil, Aysegul Altintop | |
dc.contributor.author | Kiran, Tugba Raika | |
dc.contributor.author | Berber, Nurcan Kirici | |
dc.contributor.author | Otlu, Onder | |
dc.contributor.author | Erdem, Mehmet | |
dc.contributor.author | In, Erdal | |
dc.date.accessioned | 2024-08-04T20:57:19Z | |
dc.date.available | 2024-08-04T20:57:19Z | |
dc.date.issued | 2022 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Background and Objectives: Carbonic anhydrase (CA) enzymes are a family of metalloenzymes that contain a zinc ion in their active sites. CA enzymes have been implied in important situations such as CO2 transport, pH regulation, and oncogenesis. CA-IX is a transmembrane glycoprotein and stimulates the expression of hypoxia-inducible factor-1 (HIF-1) CA-IX. This study aimed to determine serum CA-IX levels in OSA patients in whom intermittent hypoxia is important and to investigate the relationship between serum CA-IX levels and disease severity. Materials and Methods: The study included 88 people who applied to Malatya Turgut Ozal University Training and Research Hospital Sleep Disorders Center without a history of respiratory disease, malignancy, and smoking. Patients were divided into three groups: control (AHI < 5, n = 31), mild-moderate OSA (AHI = 5-30, n = 27) and severe OSA (AHI > 30, n = 30). The analysis of the data included in the research was carried out with the SPSS (IBM Statistics 25, NY, USA). The Shapiro-Wilk Test was used to check whether the data included in the study had a normal distribution. Comparisons were made with ANOVA in multivariate groups and the t-test in bivariate groups. ANCOVA was applied to determine the effect of the CA-IX parameter for OSA by controlling the effect of independent variables. The differentiation in CA-IX and OSA groups was analyzed regardless of BMI, age, gender, and laboratory variables. ROC analysis was applied to determine the parameter cut-off point. Sensitivity, specificity, and cut-off were calculated, and the area under the curve (AUC) value was calculated. Results: Serum CA-IX levels were 126.3 +/- 24.5 pg/mL in the control group, 184.6 +/- 59.1 pg/mL in the mild-moderate OSA group, and 332.0 +/- 39.7 pg/mL in the severe OSA group. Serum CA-IX levels were found to be higher in the severe OSA group compared to the mild-moderate OSA group and control group and higher in the mild-moderate OSA group compared to the control group (p < 0.001, p < 0.001, p < 0.001, respectively). In addition, a negative correlation between CA-IX and minimum SaO(2) and mean SaOI(2) (r = -0.371, p = 0.004; r = -0.319, p = 0.017, respectively). A positive correlation between CA-IX and desaturation index (CT90) was found (r = 0.369, p = 0.005). A positive correlation was found between CA-IX and CRP (r = 0.340, p = 0.010). When evaluated by ROC curve analysis, the area under the curve (AUC) value was determined as 0.940 (95% CI 0.322-0.557; p < 0.001). When the cut-off value for CA-IX was taken as 254.5 pg/mL, it was found to have 96.7% sensitivity and 94.8% specificity in demonstrating severe OSA. Conclusions: Our study found that serum CA-IX value was higher in OSA patients than in control patients, and this elevation was associated with hypoxemia and inflammation. CA-IX value can be a fast, precise, and useful biomarker to predict OSA. | en_US |
dc.identifier.doi | 10.3390/medicina58111643 | |
dc.identifier.issn | 1010-660X | |
dc.identifier.issn | 1648-9144 | |
dc.identifier.issue | 11 | en_US |
dc.identifier.pmid | 36422182 | en_US |
dc.identifier.uri | https://doi.org/10.3390/medicina58111643 | |
dc.identifier.uri | https://hdl.handle.net/11616/102533 | |
dc.identifier.volume | 58 | en_US |
dc.identifier.wos | WOS:000895152100001 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Mdpi | en_US |
dc.relation.ispartof | Medicina-Lithuania | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | CA-IX | en_US |
dc.subject | intermittent hypoxia | en_US |
dc.subject | OSA | en_US |
dc.title | Carbonic Anhydrase IX as a Marker of Disease Severity in Obstructive Sleep Apnea | en_US |
dc.type | Article | en_US |